ECSP22040921A - Composición farmacéutica que comprende selexipag - Google Patents

Composición farmacéutica que comprende selexipag

Info

Publication number
ECSP22040921A
ECSP22040921A ECSENADI202240921A ECDI202240921A ECSP22040921A EC SP22040921 A ECSP22040921 A EC SP22040921A EC SENADI202240921 A ECSENADI202240921 A EC SENADI202240921A EC DI202240921 A ECDI202240921 A EC DI202240921A EC SP22040921 A ECSP22040921 A EC SP22040921A
Authority
EC
Ecuador
Prior art keywords
selexipag
pharmaceutical composition
diphenylpyrazin
butyloxy
isopropylamino
Prior art date
Application number
ECSENADI202240921A
Other languages
English (en)
Inventor
Alexandra Schlicker-Spain
Marc Schrader
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of ECSP22040921A publication Critical patent/ECSP22040921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas que comprenden 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(metilsulfonil)acetamida (selexipag, NS-304, ACT-293987) que son adecuadas para la administración oral (p.o.).
ECSENADI202240921A 2019-10-23 2022-05-20 Composición farmacéutica que comprende selexipag ECSP22040921A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019078905 2019-10-23

Publications (1)

Publication Number Publication Date
ECSP22040921A true ECSP22040921A (es) 2022-06-30

Family

ID=75620412

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202240921A ECSP22040921A (es) 2019-10-23 2022-05-20 Composición farmacéutica que comprende selexipag

Country Status (15)

Country Link
US (1) US20220401441A1 (es)
EP (1) EP4048235A1 (es)
JP (2) JP7646646B2 (es)
KR (1) KR20220087443A (es)
CN (1) CN114555088A (es)
AU (1) AU2020369912A1 (es)
BR (1) BR112022007207A2 (es)
CA (1) CA3154802A1 (es)
EC (1) ECSP22040921A (es)
IL (1) IL292354A (es)
JO (1) JOP20220093A1 (es)
MX (1) MX2022004882A (es)
PE (1) PE20221455A1 (es)
PH (1) PH12022550937A1 (es)
WO (1) WO2021078835A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022005277A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Yaş granülasyon i̇le i̇şlenmi̇ş seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022005273A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022005274A1 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet
TR2022020995A1 (tr) * 2022-12-28 2024-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r tablet formülasyonu
CN116392491A (zh) * 2023-04-11 2023-07-07 广东省实验动物监测所 司来帕格的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
USRE46364E1 (en) 2008-02-28 2017-04-11 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
PT2292231E (pt) 2008-06-23 2015-12-31 Nippon Shinyaku Co Ltd Agente terapêutico para a estenose do canal espinal
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8394793B2 (en) 2008-06-23 2013-03-12 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
KR20250107951A (ko) 2009-06-26 2025-07-14 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
MX2014001496A (es) 2011-08-12 2014-04-30 Ascendis Pharma As Composicion de liberacion sostenida de prostaciclina.
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
SI4331607T1 (sl) * 2015-12-02 2025-06-30 Nippon Shinyaku Co., Ltd. Trdni farmacevtski sestavek, ki vsebuje 2-{4-[n-(5,6-difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil)acetamid
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
BR112020016230A2 (pt) * 2018-02-21 2020-12-08 Nippon Shinyaku Co., Ltd. Composição granular, método para produção de composição granular, e método para melhoria da propriedade de dissolução de composição granular
WO2020225297A1 (en) * 2019-05-06 2020-11-12 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension

Also Published As

Publication number Publication date
IL292354A (en) 2022-06-01
US20220401441A1 (en) 2022-12-22
JP2022553313A (ja) 2022-12-22
EP4048235A1 (en) 2022-08-31
CN114555088A (zh) 2022-05-27
AU2020369912A1 (en) 2022-04-14
BR112022007207A2 (pt) 2022-07-26
MX2022004882A (es) 2022-08-04
KR20220087443A (ko) 2022-06-24
CA3154802A1 (en) 2021-04-29
PH12022550937A1 (en) 2023-06-14
JOP20220093A1 (ar) 2023-01-30
JP7646646B2 (ja) 2025-03-17
JP2025074286A (ja) 2025-05-13
PE20221455A1 (es) 2022-09-21
WO2021078835A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
DOP2019000250A (es) Composicion farmaceutica que comprende selexipag
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MX383804B (es) Derivados de piperidina.
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EP4501404A3 (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
EP3773900A4 (en) HINOKITIOL ANALOGUES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
MX382609B (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
CY1125762T1 (el) Νεα απο του στοματος σκευασματα βελινοστατης
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
CR20220174A (es) Composición farmacéutica que comprende selexipag
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
MX2023012062A (es) Composiciones para el cuidado bucal que comprenden copolimero de bloque.
SA519410561B1 (ar) عوامل صيدلية، تركيبات، وطرق تتعلق بذلك